Shandong Xinhua Pharmaceutical (000756) Fundamentals 2026 — P/E 35.8x, Revenue Analysis | SniperIQ
Shandong Xinhua Pharmaceutical (000756) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥6.8B, trading at ¥13.48 on the SHZ. This SniperIQ fundamentals page covers Shandong Xinhua Pharmaceutical's valuation (P/E 35.8x, P/B 1.8x), profitability (net margin 3.0%), revenue (¥8.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shandong Xinhua Pharmaceutical's market cap?
Shandong Xinhua Pharmaceutical (000756) has a market capitalization of approximately ¥6.8B, trading at ¥13.48 on the SHZ. Market cap moves with the live share price.
What is Shandong Xinhua Pharmaceutical's P/E ratio?
Shandong Xinhua Pharmaceutical's trailing twelve-month P/E ratio is 35.8x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shandong Xinhua Pharmaceutical?
Shandong Xinhua Pharmaceutical runs a net profit margin of 3.0%, a gross margin of 18.6%, and an operating margin of 4.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shandong Xinhua Pharmaceutical generate?
Shandong Xinhua Pharmaceutical reported revenue of ¥8.7B for fiscal year 2025, with net income of ¥290M and earnings per share (EPS) of 0.42. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shandong Xinhua Pharmaceutical pay a dividend?
Shandong Xinhua Pharmaceutical offers a trailing dividend yield of about 2.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shandong Xinhua Pharmaceutical financially healthy?
Shandong Xinhua Pharmaceutical carries a debt-to-equity ratio of 0.36x and a current ratio of 1.76x, with a market beta of -0.03. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shandong Xinhua Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shandong Xinhua Pharmaceutical (000756) the key facts are: market cap ¥6.8B, P/E 35.8x, revenue ¥8.7B, 52-week range 11.71-18.7. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shandong Xinhua Pharmaceutical's full fundamentals live
Get Shandong Xinhua Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.